Looking for markers that predict mild cognitive impairment turning into dementia
Follows people with mild cognitive impairment over 5 years to find markers of dementia.
Key facts
- Who runs it
- Cuibai Wei,Clinical Professor
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)
- Status
- Recruiting
- People taking part
- 900 people, planned
- Started
- 28 Feb 2023
- Expected to end
- 28 Feb 2028
- Type of study
- Observational, 2 groups
- Record updated
- 24 July 2025
Who can take part
The trial is looking for people with mild cognitive impairment (MCI, mild memory and thinking problems) or dementia. They will be followed for 5 years to find markers that show who goes on to dementia.
- Age
- 50 to 85 years
- Sex
- Men and women
- Disease stage
- A diagnosis of dementia or MCI. Memory test scores: MMSE 15-28 points and CDR of 1 point or less.
- Main reasons for not taking part
- Other brain or nerve diseases that can affect thinking, such as depression, brain tumors, Parkinson's disease or epilepsy
- Other body-wide illnesses that can affect thinking, such as liver or kidney problems, thyroid problems, severe anemia, syphilis, HIV infection, or alcohol and drug abuse
- Being unable to complete the memory and thinking tests
- Being unable to have an MRI scan
- Mental or developmental delay, or refusing blood draws
Show the full registry criteria (2)Hide the full registry criteria
Who can take part
- Male or female patients aged ≥50 and ≤85 years; Meet the diagnostic criteria for dementia or MCI; ③ Neuropsychological score: MMSE 15-28 points, CDR≤1 point; ④ The patients and their families were informed and signed the informed consent
Who cannot take part
- There are other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.); There are other systemic diseases that can cause cognitive impairment (such as hepatic insufficiency, renal insufficiency, Thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.); Suffering from a disease that cannot cooperate with the completion of cognitive examination; ④ There are contraindications to nuclear magnetic resonance; There is mental and neurodevelopmental delay; ⑥ refuse to draw blood; ⑦ Refuse to sign the informed consent
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Biomarkers or MCI conversion to dementia
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects more than 15% of the population over the age of 60 in China. About 15% patients with MCI could progress into dementia after two years and about one-third develop into dementia within five years, which will lead to suffering, as well as staggering economic and care burden. So, exploring the predicting biomarkers from MCI to dementia to identify and delay progression to dementia at an early stage is of great social and clinical significance. Some reports based on a single neural biomarker suggest that risk models can predict the conversion of MCI to dementia, but no widely recognized prediction models basing on multiple complex markers have been used in clinical practice. The objectives of this study are to outline the spectrum of MCI transforming into dementia through a 5-year prospective longitudinal cohort study; Secondly, screening biomarkers for MCI transmit to dementia are based on clinical symptoms, neuropsychology, neuroimaging, neuroelectrophysiology, and humoral markers tests data.
The 2 groups in the trial
- MCI progression
MCI-P (Compared with the baseline, MMSE score declined \> 4 points per year)
- MCI stabilization
MCI-S (Compared with the baseline, MMSE score decreased \< 4 points per year)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Studies on Biomarkers for Mild Cognitive Impairment Conversion to Dementia
- Plain-language title
- Looking for markers that predict mild cognitive impairment turning into dementiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT05697588, who can take part
- Record updated
- 24 July 2025